Onestepahead, I recall the discussion of a redu
Post# of 148337
(Total Views: 559)
Posted On: 02/01/2022 1:24:18 PM
Re: onestepahead #116879
Onestepahead,
I recall the discussion of a reduction of enrollment in both trials. I believe that was an attempt to deal with the dearth of patients late 2021. With the onslaught of omicron, I believe those plans were shelved and the original enrollment goals maintained.
Trials registries were update on January 4, with critical enrolling 316 at 23 sites and moderate enrolling 612 at 27 sites.
It would be nice to know, in addition to enrollment figures, how the meta analysis will be conducted and at what intervals the DSMB will conduct analyses.
moderate: https://clinicaltrials.gov/ct2/show/NCT049016...amp;rank=1
critical: https://clinicaltrials.gov/ct2/show/NCT049016...amp;rank=1
I recall the discussion of a reduction of enrollment in both trials. I believe that was an attempt to deal with the dearth of patients late 2021. With the onslaught of omicron, I believe those plans were shelved and the original enrollment goals maintained.
Trials registries were update on January 4, with critical enrolling 316 at 23 sites and moderate enrolling 612 at 27 sites.
It would be nice to know, in addition to enrollment figures, how the meta analysis will be conducted and at what intervals the DSMB will conduct analyses.
moderate: https://clinicaltrials.gov/ct2/show/NCT049016...amp;rank=1
critical: https://clinicaltrials.gov/ct2/show/NCT049016...amp;rank=1
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼